| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding | |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | Entrez:933 MIM:107266 HGNC:HGNC:1643 Ensembl:ENSG00000012124 AllianceGenome:HGNC:1643 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | CD22 molecule | |||||
| GTO ID | GTC3718 |
| Trial ID | NCT06208735 |
| Disease | B-Cell Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B Cell Lymphoma | High-Grade B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CLIC-2201 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies |
| Year | 2024 |
| Country | Canada |
| Company sponsor | British Columbia Cancer Agency |
| Other ID(s) | CLIC-02 |
| Cohort 1 | |||||||||||
|
|||||||||||